AKBA Akebia Therapeutics Inc.

$AKBA So what's new about today's Voice trial PR? A LOT!! (Multipart thread) What we knew from 06/30/26 top level Voice results PR was that patients on Vafseo had 10% less hospitalization rates than ESAs. Awesome, but today we found out about some extra benefits of Vafseo use, which was just presented at 2026 ASN by Dr Block last week. Patients on Vafseo (vs ESAs) had 64% reduction in odds of Hb going above 12 (29.6% vs 51.2%, p<0.0001) with p score showing as high statistical significance as u can get. Similar superiority of Vafseo for less Hb excursions for 13 and 14 levels. The best part is NO difference on the bottom end for below 7, 8, and 9 levels. So u get best of both worlds with Vafseo. Also the odds of ESA rescue were 28% less likely with Vafseo patients vs ESAs (44.6% vs 52.8% p=0.0006), again p value is low enough to show strong stat significance.

$AKBA Akebia is about to drop a 💣 on short sellers with positive Vocal results. As trial sponsor, the PR will come from Akebia, hopefully with strong quotes from Davita including a commitment on Vafseo adoption. I believe news is imminent. Prepare!

$AKBA The day that I finally hold zero shares of this company will likely rival the birth of my children for best day of my life. For some reason that I cannot fathom, l am still holding a good chunk of shares and even started adding in the last couple of weeks. I sincerely just want this to end.

$AKBA Real interesting stuff discussed yesterday (Multipart thread) Thanks primarily to we got some commentary from a leading nephro. Let me try to sum up and maybe even extrapolate a bit on what was discussed. Feel free to add. Nephros even at USRC are still trying to optimize Vafseo use protocol since Vafseo seems to have more advantages then previously thought and a major one came first seen in April 2026 where they noticed Vafseo has a different MOA that helps reduce ESA hyporesponsiveness (ie ESA resistance), making ESA rescue have stronger positive effects and reduce the frequency and dose of its need, even for ESA hyporesponders. Looking back at the data, the Focus TIW study did show that, and Butler did say on numerous occasions the Vafseo arm needed, like 50% less ESA rescues than the ESA arm. Now for me itbis making more sense. That being said, USRC is running a trial to better characterize this added Vafseo positive benefit and add it to their protocol.

$AKBA BUSINESS NOT AS USUAL (1)CCO Grund fails miserably, resigns in Nov. ’26, for ”personal reasons”, but will remain until April 30, ’27 to consult & advise; (2)VP Med. Affairs Minga exits for SCYNEXIS & Sr. VP, Chief R&D, Chief Med. Ofc. Burke takes BOD position at SYNEXIS, both in Sept. ’26; (3)Akebia cuts workforce by 20% in June/July ’26; (4)Akebia leased cheaper space in Jan. ’26 from BP Third Ave.; (5)CEO Butler & CFO Ostrowski amend severance agreements favorably in Jan. ’26 in the event of a Change In Control; (6)Tutes crush share price from $4.08 to $0.6457, while Akebia offers no vigorous share price defense, even though the co. has data to do so; (6)Akebia participates in three straight events without an open forum or Q&A session. Thoughts?

$AKBA Dear Mr. Butler: We no longer have confidence in your ability to create shareholder value. For this reason, we ask that you answer the following questions to the best of your professional ability so that we may make informed ”buy-sell” decisions before the end of the year: (1)Will sales of Vafseo in Japan, Europe, et. al. generate royalties to increase stock price? If so, how much? (2)Will Auryxia sales decrease stock price? If so, how much? (3)Will Vafseo DD USA sales offset Auryxia losses sufficiently to increase price? If so, how much? (4)Will the pipeline (Vadadustat NDD, Vadadustat Covid-19/ARDS, Praliciguat, AKB-097, AKB-9090 (AKI/ARDS), AKB-10108 (ROP/BPD), AKB Cancer/Oncology) generate an increase in price? If so, how much? (5)Is Akebia acting immediately to increase stock price? If so, what are you doing?

$AKBA some of you call me a pumper I’m not. I’m just consistently positive in all aspects of my life. If I wasn’t I’d be in a wheel chair! I have always had a good feeling about this company and I roll with it. Call it intuition or that little voice in my head, don’t know but I pay more attention to it these days and I act. It’s been working out. Perhaps we as humans have lost the ability to hear those notions. Maybe that’s how the universe is supposed to work but that little whisper was saying “Load the boat bitch” so I did with as much as I could muster!! Good luck!

$AKBA This should make everyone feel better, except those that sold! It will make most feel smarter than they thought! Look at what the average buy in price for the funds are! You are in good company!

$AKBA U.S. Renal Care, nation’s fastest growing kidney care provider, presented data from Vafseo Outcome In Center Experience (VOICE) at Amer. Society of Nephrology Kidney Week 2026 which revealed that Vafseo had (1)significantly improved safety & clinically meaningful outcomes in patients treated w/ vadadustat v. an ESA; (2)more stable hemoglobin control, fewer high hemoglobin excursions; (3)odds of ESA rescue were less; (4)fewer exposure adjusted serious adverse events; (5)significant reductions w/ primary composite endpoint of all-cause mortality & hospitalizations; (6)hospitalization rate 10% lower (statistically significant); etc. Vafseo is positioned to become new standard of care. Release the VOCAL data. Save chronically ill Americans. Good luck to all of our honest investors.

$AKBA SOC is inevitable: Vafseo not only is superior on operational and logistical terms for dialysis centers, it saves those centers hundreds of millions in hospitalization and is simply a better treatment for anemia, period. In big cities and areas with fierce competition, any dialysis center that does not provide patients with Vafseo will lose these patiences to those who do. Added litigation Risk in any new death as of current publication and there you go!

$AKBA DaVita is still learning how to administer V and get their protocol right. Per Holy boy, patients with ESA resistance drop their HGB fast when converted to V and need rescue ESA address HBG drop. He administers rescue ESA when HBG drops below 9.5. Learning from the trails and treatment of patients requires the fine tuning of the protocols. But with data from the Voice trail, V will become SOC. We are just taking the long path there!

$AKBA that being said, a buyout is upside optionality that may or may not occur, and should be considered by management if the offer is fair. Other upside optionality is the possibility of CMS rule changes that help incentivize innovative therapies such as vafseo, KCAPA passing, catalysts from pipeline readouts. I believe there is a policy tailwind from the recent HHS statement on kidney care. The issues of attempting to break into a duopoly with a bundled payment structure has been identified and I expect measures to follow to begin to correct the structural flaw. The one I am personally hoping for is for them to transition from the peanut butter spread reimbursement for all DOs to a more targeted increase for only the clinics that utilize the innovative therapy. These things are clearly not represented in current share price. Good luck to us all, I do hope we see better days in the coming months and years.

$AKBA At $0.54, this stock was priced as if everything were going wrong. I don’t expect spectacular Q3 earnings, and 2027 still carries uncertainty. But with VOICE, CMS changes, KCAPA and other potential catalysts ahead, I see far more upside potential than this valuation suggests. $4, $7 or even $10 aren’t guaranteed, but neither is the worst-case scenario the market seems to be pricing in… GL

$AKBA ASN poster abstract - Residual Kidney Function Is Associated with Hyporesponsiveness to Erythropoiesis-Stimulating Agents but Not Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in Patients on Peritoneal Dialysis Small sample and in PD (not HD)

$AKBA The $0.50's were significant to the grand scheme of things. Monthly chart of all time shows divergence surrounding the CRL time period but has so far established back within the slightly expanding channel that connects the major highs and lows. The most volume traded since the all time low was traded at $0.9278 (Point of Control). The most volume since the last swing high is almost at exactly the same level which is at $0.9159. Makes sense why last month's candle was a doji exactly at that level as bulls and bears fought it out with 146.7MM shares just to end up exactly where the month started.

$AKBA Intraday candles starting from the 26th showing an ascending support trend as it is converging with longer-term descending resistance:

$AKBA Hell that was fun! Let’s do it again tomorrow! Maybe we fire up the grill? I thought I smelled a slight Smokey aroma in the breeze kinda made me hungry! 🤤 Hahaha!😂

$AKBA Is there a single acquirer who wants the whole company? Below is an illustrative analytical judgment, not reported M&A interest · scores 0–5 · value-weighted whole-company interest (Vafseo 42%, ebribafusp 36%, pipeline 22%) - they are not further weighted by POS (prob. of success). The strongest fit for each asset lands with a different buyer — CSL/Amgen on Vafseo, AstraZeneca/Alexion & Novartis on ebribafusp, Amgen on the AAV backfill, Bayer or Vertex on praliciguat, AstraZeneca on AKB-9090. AstraZeneca is the most mechanism-overlapping buyer (complement + HIF), yet even it skips the dialysis franchise. That favours an asset-level break-up or out-licensing over one clean premium takeout. Pipeline scores assume the asset reads out; Vafseo is already approved. Lets see how things pan out from here.

$AKBA It’s not fading folks. Been awhile sinse we had a gap up for open? We shall see. Enjoy your evening and GL

$AKBA Interesting facts. Company has never reverse split. Even in 2023 when price was this low. They found a way to move back up.